Application of Circulating Tumor Cells and Interleukin-6 in Preoperative Prediction of Peritoneal Metastasis of Advanced Gastric Cancer

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Thomassen I, van Gestel YR, van Ramshorst B, et al. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer. 2014;134(3):622–628. doi:10.1002/ijc.28373
   PubMed Web of Science ®Google Scholar
• Fujitani K, Yang HK, Mizusawa J, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a Phase 3, randomised controlled trial. Lancet Oncol. 2016;17(3):309–318. doi:10.1016/S1470-2045(15)00553-7
   PubMed Web of Science ®Google Scholar
• Coccolini F, Gheza F, Lotti M, et al. Peritoneal carcinomatosis. World J Gastroenterol. 2013;19(41):6979–6994. doi:10.3748/wjg.v19.i41.6979
   PubMed Web of Science ®Google Scholar
• Yonemura Y, Prabhu A, Sako S, et al. Long term survival after cytoreductive surgery combined with perioperative chemotherapy in gastric cancer patients with peritoneal metastasis. Cancers. 2020;12(1):116. doi:10.3390/cancers12010116
   PubMed Web of Science ®Google Scholar
• Gamboa AC, Winer JH. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for gastric cancer. Cancers. 2019;11(11):1662. doi:10.3390/cancers11111662
   PubMed Web of Science ®Google Scholar
• Bonnot PE, Piessen G, Kepenekian V, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. J Clin Oncol. 2019;37(23):2028–2040. doi:10.1200/JCO.18.01688
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016;388(10060):2654–2664. doi:10.1016/S0140-6736(16)30354-3
   PubMed Web of Science ®Google Scholar
• Sato Y, Ohnuma H, Nobuoka T, et al. Conversion therapy for inoperable advanced gastric cancer patients by docetaxel, cisplatin, and S-1 (DCS) chemotherapy: a multi-institutional retrospective study. Gastric Cancer. 2017;20(3):517–526. doi:10.1007/s10120-016-0633-1
   PubMed Web of Science ®Google Scholar
• Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v38–v49. doi:10.1093/annonc/mdw350
   PubMedGoogle Scholar
• Diop AD, Fontarensky M, Montoriol PF, Da Ines D. CT imaging of peritoneal carcinomatosis and its mimics. Diagn Interv Imaging. 2014;95(9):861–872. doi:10.1016/j.diii.2014.02.009
   PubMed Web of Science ®Google Scholar
• Kim SJ, Kim HH, Kim YH, et al. Peritoneal metastasis: detection with 16- or 64-detector row CT in patients undergoing surgery for gastric cancer. Radiology. 2009;253(2):407–415. doi:10.1148/radiol.2532082272
   PubMed Web of Science ®Google Scholar
• Kwee RM, Kwee TC. Modern imaging techniques for preoperative detection of distant metastases in gastric cancer. World J Gastroenterol. 2015;21(37):10502–10509. doi:10.3748/wjg.v21.i37.10502
   PubMed Web of Science ®Google Scholar
• Burbidge S, Mahady K, Naik K. The role of CT and staging laparoscopy in the staging of gastric cancer. Clin Radiol. 2013;68(3):251–255. doi:10.1016/j.crad.2012.07.015
   PubMed Web of Science ®Google Scholar
• Dong D, Tang L, Li ZY, et al. Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer. Ann Oncol. 2019;30(3):431–438. doi:10.1093/annonc/mdz001
   PubMed Web of Science ®Google Scholar
• Shimada H, Okazumi S, Koyama M, Murakami K. Japanese Gastric Cancer Association Task Force for Research Promotion: clinical utility of 18F-fluoro-2-deoxyglucose positron emission tomography in gastric cancer. A systematic review of the literature. Gastric Cancer. 2011;14(1):13–21. doi:10.1007/s10120-011-0017-5
   PubMed Web of Science ®Google Scholar
• Fukagawa T. Role of staging laparoscopy for gastric cancer patients. Ann Gastroenterol Surg. 2019;3(5):496–505. doi:10.1002/ags3.12283
   PubMed Web of Science ®Google Scholar
• Li K, Cannon JGD, Jiang SY, et al. Diagnostic staging laparoscopy in gastric cancer treatment: a cost-effectiveness analysis. J Surg Oncol. 2018;117(6):1288–1296. doi:10.1002/jso.24942
   PubMed Web of Science ®Google Scholar
• Yap TA, Lorente D, Omlin A, Olmos D, de Bono JS. Circulating tumor cells: a multifunctional biomarker. Clin Cancer Res. 2014;20(10):2553–2568. doi:10.1158/1078-0432.CCR-13-2664
   PubMed Web of Science ®Google Scholar
• Lee MW, Kim GH, Jeon HK, Park SJ. Clinical application of circulating tumor cells in gastric cancer. Gut Liver. 2019;13(4):394–401. doi:10.5009/gnl18484
   PubMed Web of Science ®Google Scholar
• Jhi JH, Kim GH, Park SJ, et al. Circulating tumor cells and TWIST expression in patients with metastatic gastric cancer: a preliminary study. J Clin Med. 2021;10(19):4481. doi:10.3390/jcm10194481
   PubMed Web of Science ®Google Scholar
• Thanh Huong P, Gurshaney S, Thanh Binh N, et al. Emerging role of circulating tumor cells in gastric cancer. Cancers. 2020;12(3):695. doi:10.3390/cancers12030695
   PubMed Web of Science ®Google Scholar
• Pantel K, Alix-Panabières C. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med. 2010;16(9):398–406. doi:10.1016/j.molmed.2010.07.001
   PubMed Web of Science ®Google Scholar
• Oya Y, Hayakawa Y, Koike K. Tumor microenvironment in gastric cancers. Cancer Sci. 2020;111(8):2696–2707. doi:10.1111/cas.14521
   PubMed Web of Science ®Google Scholar
• Bockerstett KA, DiPaolo RJ. Regulation of gastric carcinogenesis by inflammatory cytokines. Cell Mol Gastroenterol Hepatol. 2017;4(1):47–53. doi:10.1016/j.jcmgh.2017.03.005
   PubMed Web of Science ®Google Scholar
• Yang E, Chua W, Ng W, Roberts TL. Peripheral cytokine levels as a prognostic indicator in gastric cancer: a review of existing literature. Biomedicines. 2021;9(12):1916. doi:10.3390/biomedicines9121916
   PubMed Web of Science ®Google Scholar
• Gunjigake K, Kinoshita J, Yamaguchi T, et al. Interleukin-17A derived from mast cells contributes to fibrosis in gastric cancer with peritoneal dissemination. Gastric Cancer. 2021;24(1):31–44. doi:10.1007/s10120-020-01092-2
   PubMed Web of Science ®Google Scholar
• Zheng Z, Bu Z, Liu X, et al. Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications. Chin J Cancer Res. 2014;26(1):104–111. doi:10.3978/j.issn.1000-9604.2014.02.08
   PubMed Web of Science ®Google Scholar
• Zou K, Yang S, Zheng L, Wang S, Xiong B. Prognostic role of the circulating tumor cells detected by cytological methods in gastric cancer: a meta-analysis. Biomed Res Int. 2016;2016:2765464. doi:10.1155/2016/2765464
   PubMed Web of Science ®Google Scholar
• Mishima Y, Matsusaka S, Chin K, et al. Detection of HER2 amplification in circulating tumor cells of HER2-negative gastric cancer patients. Target Oncol. 2017;12(3):341–351. doi:10.1007/s11523-017-0493-6
   PubMed Web of Science ®Google Scholar
• Yue C, Jiang Y, Li P, et al. Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy. Oncoimmunology. 2018;7(7):e1438111. doi:10.1080/2162402X.2018.1438111
   PubMed Web of Science ®Google Scholar
• Okabe H, Tsunoda S, Hosogi H, et al. Circulating tumor cells as an independent predictor of survival in advanced gastric cancer. Ann Surg Oncol. 2015;22(12):3954–3961. doi:10.1245/s10434-015-4483-6
   PubMed Web of Science ®Google Scholar
• Uenosono Y, Arigami T, Kozono T, et al. Clinical significance of circulating tumor cells in peripheral blood from patients with gastric cancer. Cancer. 2013;119(22):3984–3991. doi:10.1002/cncr.28309
   PubMed Web of Science ®Google Scholar
• Sánchez-Zauco N, Torres J, Gómez A, et al. Circulating blood levels of IL-6, IFN-γ, and IL-10 as potential diagnostic biomarkers in gastric cancer: a controlled study. BMC Cancer. 2017;17(1):384. doi:10.1186/s12885-017-3310-9
   PubMedGoogle Scholar
• Kim DK, Oh SY, Kwon HC, et al. Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer. 2009;9:155. doi:10.1186/1471-2407-9-155
   PubMed Web of Science ®Google Scholar
• Li J, Xu L, Run ZC, et al. Multiple cytokine profiling in serum for early detection of gastric cancer. World J Gastroenterol. 2018;24(21):2269–2278. doi:10.3748/wjg.v24.i21.2269
   PubMed Web of Science ®Google Scholar
• Huang C, Liu Z, Xiao L, et al. Clinical significance of serum CA125, CA19-9, CA72-4, and fibrinogen-to-lymphocyte ratio in gastric cancer with peritoneal dissemination. Front Oncol. 2019;9:1159. doi:10.3389/fonc.2019.01159
   PubMed Web of Science ®Google Scholar
• Yang C, Yang Y, Huang X, et al. A nomogram based on clinicopathologic features and preoperative hematology parameters to predict occult peritoneal metastasis of gastric cancer: a single-center retrospective study. Dis Markers. 2020;2020:1418978. doi:10.1155/2020/1418978
   PubMed Web of Science ®Google Scholar
• Chen XD, Mao CC, Wu RS, et al. Use of the combination of the preoperative platelet-to-lymphocyte ratio and tumor characteristics to predict peritoneal metastasis in patients with gastric cancer. PLoS One. 2017;12(4):e0175074. doi:10.1371/journal.pone.0175074
   PubMed Web of Science ®Google Scholar
• Qin R, Yang Y, Qin W, et al. The value of serum immunoglobulin G glycome in the preoperative discrimination of peritoneal metastasis from advanced gastric cancer. J Cancer. 2019;10(12):2811–2821. doi:10.7150/jca.31380
   PubMed Web of Science ®Google Scholar
• Liu Z, Ge H, Miao Z, Shao S, Shi H, Dong C. Dynamic changes in the systemic inflammation response index predict the outcome of resectable gastric cancer patients. Front Oncol. 2021;11:577043. doi:10.3389/fonc.2021.577043
   PubMed Web of Science ®Google Scholar
• Zhang LX, Wei ZJ, Xu AM, Zang JH. Can the neutrophil-lymphocyte ratio and platelet-lymphocyte ratio be beneficial in predicting lymph node metastasis and promising prognostic markers of gastric cancer patients? Tumor maker retrospective study. Int J Surg. 2018;56:320–327. doi:10.1016/j.ijsu.2018.06.037
   PubMed Web of Science ®Google Scholar
• Zhao J, Qin R, Chen H, et al. A nomogram based on glycomic biomarkers in serum and clinicopathological characteristics for evaluating the risk of peritoneal metastasis in gastric cancer. Clin Proteomics. 2020;17:34. doi:10.1186/s12014-020-09297-4
   PubMed Web of Science ®Google Scholar
• Nakamura N, Kinami S, Fujii Y, et al. The neutrophil/lymphocyte ratio as a predictor of peritoneal metastasis during staging laparoscopy for advanced gastric cancer: a retrospective cohort analysis. World J Surg Oncol. 2019;17(1):108. doi:10.1186/s12957-019-1651-3
   PubMedGoogle Scholar
• Chen Y, Zhou Q, Wang H, et al. Predicting peritoneal dissemination of gastric cancer in the era of precision medicine: molecular characterization and biomarkers. Cancers. 2020;12(8):2236. doi:10.3390/cancers12082236
   PubMed Web of Science ®Google Scholar
• Chen X, Chen S, Wang X, et al. Analysis and external validation of a nomogram to predict peritoneal dissemination in gastric cancer. Chin J Cancer Res. 2020;32(2):197–207. doi:10.21147/j.issn.1000-9604.2020.02.07
   PubMed Web of Science ®Google Scholar